Indeed, tyrosine kinase inhibitors (TKI) targeting oncogenes such as cABL (activated in Philadelphia chromosome-positive chronic myeloid leukemia, CML)1, BRAF (activated in melanoma)2, ERBB2 (activated in a fraction of breast cancers)3, EGFR (activated in a sizable portion of non-small cell lung cancers, NSCLC)4, KIT (activated in gastrointestinal stromal tumors, GIST)5, or VGFR (activated in renal cancers and others)6, have been approved for the routine treatment of cancer patients. Here, BRAF is linked to non-small cell lung carcinoma.